Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
February 27, 2020 07:30 ET | Adaptimmune Therapeutics plc
- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 - - Encouraging...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020
February 20, 2020 16:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer
February 18, 2020 08:00 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2020 16:05 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
January 24, 2020 16:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
January 22, 2020 08:48 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
January 21, 2020 16:08 ET | Adaptimmune Therapeutics plc
PHILADELPHIA, Pa. and OXFORD, UK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer...
Adaptimmune logo Colour_white background_no strap.jpg
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
January 14, 2020 02:07 ET | Adaptimmune Therapeutics plc
- Agreement covers the co-development and co-commercialization of up to three T-cell therapies - - Agreement leverages Astellas’ Universal Donor Cell Platform and Adaptimmune’s stem-cell derived...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership
January 13, 2020 08:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, today announced the...
Adaptimmune logo Colour_white background_no strap.jpg
Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma
December 03, 2019 08:30 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it...